June 30, 2021
1 min read

 Covaxin effective against both Alpha, Delta variants: US NIH

COVAXIN comprises a disabled form of SARS-CoV-2 that cannot replicate but still stimulates the immune system to make antibodies against the virus…reports Asian Lite News

The National Institute of Health (NIH) in the United States has found that Bharat Biotech’s COVAXIN vaccine generates antibodies that effectively neutralize both Alpha and Delta variants of COVID-19.

The top health research institute said that an adjuvant developed with funding from the NIH has contributed to the success of the “highly efficacious” COVAXIN COVID-19 vaccine, which roughly 25 million people have received to date in India and elsewhere.

“Results from two studies of blood serum from people who had received COVAXIN suggest that the vaccine generates antibodies that effectively neutralize the B.1.1.7 (Alpha) and B.1.617 (Delta) variants of SARS-CoV-2, first identified in the United Kingdom and India, respectively,” NIH said in a statement.

The adjuvant used in COVAXIN, Alhydroxiquim-II, was discovered and tested in the laboratory by the biotech company ViroVax LLC of Lawrence, Kansas with support exclusively from the NIAID Adjuvant Development Program, NIH said.

ALSO READ: ‘FDA decision on Covaxin has no bearing on us’

The adjuvant comprises a small molecule attached in a unique way to Alhydrogel, a substance frequently called alum that is the most commonly used adjuvant in vaccines for people.

“Ending a global pandemic requires a global response,” said Anthony S. Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID), a part of NIH. “I am pleased that a novel vaccine adjuvant developed in the United States with NIAID support is part of an efficacious COVID-19 vaccine available to people in India.”

COVAXIN comprises a disabled form of SARS-CoV-2 that cannot replicate but still stimulates the immune system to make antibodies against the virus. Published results from a Phase 2 trial of the vaccine indicate that it is safe and well-tolerated.

Unpublished interim results from the Phase 3 trial indicate that the vaccine has 78 per cent efficacy against symptomatic disease, 100 per cent efficacy against severe COVID-19, including hospitalization, and 70 per cent efficacy against asymptomatic infection with SARS-CoV-2, the virus that causes COVID-19. (ANI)

ALSO READ: Covaxin trials on children set to begin

Previous Story

Burmese grapes from Assam exported to Dubai

Next Story

Modi holds high-level meet on security issues

Latest from -Top News

London Puts Beijing on Hold

The proposed embassy, earmarked for the site of a historic two-century-old building near the Tower of London, has been bogged down in dispute for more than three years…reports Asian Lite News The

Fiji PM Rabuka Begins First India Visit

The visit comes just weeks after India and Fiji held the 6th round of Foreign Office Consultations (FOC) in Suva, Fiji, in July 2025….reports Asian Lite News Fiji’s Prime Minister Sitiveni Ligamamada

Modi all set for Japan, China visits

By travelling to both Tokyo and Tianjin within the span of a week, Modi is set to balance strategic partnerships with Japan and cautious engagement with China – two relationships that will
Go toTop

Don't Miss

110 countries recognise India’s Covishield, Covaxin

Of eight WHO-approved vaccines against Covid-19 in emergency use listing,

Covaxin recognized by Australia

This will have significant impact for the return of international